Start your patients on Wegovy® today for as little as $0*

For the first twelve 28-day fills



*Subject to maximum savings of $225 per 28-day supply (1 box) for up to 12 fills for commercially insured patients with Wegovy® coverage. Patients with commercial insurance who do not have coverage for Wegovy® can save $500 per 28-day supply (1 box). Offer must be activated by 12/31/23. Eligibility and other restrictions apply, see WegovyTerms.com for details. Novo Nordisk reserves the right to modify or cancel this program at any time.

Help your patients get started with Wegovy® in 3 easy steps:

Verify coverage in as little as 90 seconds

Initiate a prior authorization, if needed

Start Wegovy®

Get your patients started at **WegovyCoverage.com**

Indications and Usage

Wegovy® (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in:

- adults with an initial body mass index (BMI) of ≥30 kg/m^2 (obesity) or ≥27 kg/m^2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
- pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater standardized for age and sex (obesity)

Limitations of Use

- Wegovy® contains semaglutide and should not be coadministered with other semaglutide-containing products or with any GLP-1 receptor agonist
- The safety and effectiveness of Wegovy® in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established
- Wegovy® has not been studied in patients with a history of pancreatitis

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

- **In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined**
- **Wegovy® is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Wegovy® and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Wegovy®**

Please see additional Important Safety Information throughout. Please see accompanying Prescribing Information, including Boxed Warning.

ONCE-WEEKLY
wegovy®
semaglutide injection 2.4 mg

1. VERIFY COVERAGE

Verify your patients' coverage and estimated costs in as little as 90 seconds

You can complete electronic benefit verification on:
WegovyCoverage.com

Coverage information is provided for more than 80% of submitted inquiries.

Once registered, you can learn about your patients':

- Coverage status
- Estimated co-pay amount

Your patients may have already checked their own coverage

If your patients show you that they have

WegovyVerified COVERAGE

proceed to step 2 to initiate a prior authorization, if required

Patients should call their insurance provider directly to confirm the accuracy of coverage information provided through this tool. The assessment is based upon the information provided and does not constitute a guarantee of coverage or co-pay amount.

If your patients don't have Wegovy® coverage:

You and your patients can advocate for better coverage from their insurance company or human resource department.

Important Safety Information (cont'd)

Contraindications

- Wegovy® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy®. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with Wegovy®

Warnings and Precautions

- **Risk of Thyroid C-Cell Tumors:** Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging
- **Acute Pancreatitis:** Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Acute pancreatitis was observed in patients treated with Wegovy® in clinical trials. Observe patients carefully for signs and symptoms of acute pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting). If acute pancreatitis is suspected, discontinue Wegovy® promptly, and if acute pancreatitis is confirmed, do not restart
- **Acute Gallbladder Disease:** Treatment with Wegovy® was associated with an increased occurrence of cholelithiasis and cholecystitis. The incidence of cholelithiasis and cholecystitis was higher in Wegovy® pediatric patients aged 12 years and older than in Wegovy® adults. In clinical trials in adult patients, cholelithiasis was reported by 1.6% of Wegovy® patients and 0.7% of placebo patients. Cholecystitis was reported by 0.6% of Wegovy® patients and 0.2% of placebo patients. In a clinical trial in pediatric patients aged 12 years and older, cholelithiasis was reported by 3.8% of Wegovy® patients and 0% placebo patients. Cholecystitis was reported by 0.8% of Wegovy® pediatric patients and 0% placebo patients. Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in Wegovy® patients than in placebo patients, even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated
- **Hypoglycemia:** Wegovy® lowers blood glucose and can cause hypoglycemia. In a trial of adult patients with type 2 diabetes, hypoglycemia was reported in 6.2% of Wegovy® patients versus 2.5% of placebo patients. Patients with type 2 diabetes taking Wegovy® with an insulin secretagogue (e.g. sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms. Monitor blood glucose in patients with type 2 diabetes
- **Acute Kidney Injury:** There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which in some cases required hemodialysis, in patients treated with semaglutide. Patients with renal impairment may be at a greater risk of acute kidney injury, but some

2. INITIATE PRIOR AUTHORIZATION

If a prior authorization is needed, learn more at WegovyCoverage.com

PAs may seem like a standard process, but can be denied because of documentation errors

Coverage for anti-obesity medications may vary as plans can set their own formulary restrictions. Prior authorization requirements can differ based on the plan; these tips are a general guideline.

Here are some criteria you may want to consider when completing a Wegovy® PA:

- Reason for treatment, age of patient, and BMI as they're often required for Wegovy® PA submissions
- If necessary, evidence that a patient has engaged in behavior modification and dietary restrictions for at least 3 months and has failed to achieve desired weight loss
- Supportive documentation, such as chart notes and medical forms within the past 30 days, to help support your claim

BMI, body mass index; PA, prior authorization.

Remember that potential formulary restrictions may differ from the Wegovy® label, so it's important to check your patient's plan when completing the PA.

Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

events have been reported in patients without known underlying renal disease. A majority of the events occurred in patients who experienced nausea, vomiting, or diarrhea, leading to volume depletion. Monitor renal function when initiating or escalating doses of Wegovy® in patients reporting severe adverse gastrointestinal reactions and in patients with renal impairment reporting any adverse reactions that could lead to volume depletion

- **Hypersensitivity Reactions:** Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with Wegovy®. If hypersensitivity reactions occur, discontinue use of Wegovy®, treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist
- **Diabetic Retinopathy Complications in Patients with Type 2 Diabetes:** In a trial of adult patients with type 2 diabetes, diabetic retinopathy was reported by 4.0% of Wegovy® patients and 2.7% of placebo patients. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy
- **Heart Rate Increase:** Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in Wegovy® adult patients compared to placebo in clinical trials. More Wegovy® adult patients compared with placebo had maximum changes from baseline of 10 to 19 bpm (41% versus 34%) and 20 bpm or more (26% versus 16%). In a clinical trial in pediatric patients aged 12 years and older with normal baseline heart rate, more patients treated with Wegovy® compared to placebo had maximum changes in heart rate of 20 bpm or more (54% versus 39%). Monitor heart rate at regular intervals and instruct patients to report palpitations or feelings of a racing heartbeat while at rest. If patients experience a sustained increase in resting heart rate, discontinue Wegovy®
- **Suicidal Behavior and Ideation:** Suicidal behavior and ideation have been reported in clinical trials with other weight management products. Monitor patients for depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Wegovy® in patients who experience suicidal thoughts or behaviors and avoid in patients with a history of suicidal attempts or active suicidal ideation

Please see additional Important Safety Information throughout. Please see accompanying Prescribing Information, including Boxed Warning.

ONCE-WEEKLY
wegovy®
semaglutide injection 2.4 mg

3. START WEGOVY®

Once PA is approved, patients are ready to fill their 0.25 mg Wegovy® prescription

When prescribing the escalation doses and the maintenance dose of Wegovy®, consider:

Tips for prescribing:

- If patients **receive a starter kit** that includes four 0.25 mg Wegovy® pens, **check the "samples given"** box in their EHR
  - Write prescription for 0.5 mg
- **Encourage your patients to check in** throughout their dose-escalation schedule to assess progress and tolerability
- After your patients reach their maintenance dose, you can **consider a 3-month Rx**
- Check to make sure the dispense quantity unit of measure is "mL" only
- Be sure to **always choose "semaglutide for weight management"** when searching the product database

Important to remember:

A new prescription is required for each dose strength

Integrated needle means no separate Rx or co-pay

Helpful information when writing Wegovy® prescriptions in EHR systems:

0.25 mg Starting dose NDC: 0169-4525-14	0.5 mg Escalation dose NDC: 0169-4505-14	1 mg Escalation dose NDC: 0169-4501-14	1.7 mg* Escalation or maintenance dose NDC: 0169-4517-14	2.4 mg* Recommended maintenance dose NDC: 0169-4524-14
• 0.25 mg/0.5 mL • Inject 0.25 mg SUBQ once a week for 4 weeks (28 days) • 28-day supply dispense 2 mL	• 0.5 mg/0.5 mL • Inject 0.5 mg SUBQ once a week for 4 weeks (28 days) • 28-day supply dispense 2 mL	• 1 mg/0.5 mL • Inject 1 mg SUBQ once a week for 4 weeks (28 days) • 28-day supply dispense 2 mL	• 1.7 mg/0.75 mL • Inject 1.7 mg SUBQ once a week for 4 weeks (28 days) • 28-day supply dispense 3 mL	• 2.4 mg/0.75 mL • Inject 2.4 mg SUBQ once a week for 4 weeks (28 days) • 28-day supply dispense 3 mL

EHR, electronic health record; NDC, National Drug Code; SUBQ, subcutaneously.

*A 3-month supply (84 days) for appropriate patients would be dispensed as 3 packs, each containing 4 Wegovy® 1.7 mg or 2.4 mg dose single-use pens (1.7 mg/0.75 mL or 2.4 mg/0.75 mL) for a total dispense quantity of 9 mL.

Important Safety Information (cont'd)

Adverse Reactions

- Most common adverse reactions (incidence ≥5%) are: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis

Drug Interactions

- The addition of Wegovy® in patients treated with insulin has not been evaluated. When initiating Wegovy®, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia
- Wegovy® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Wegovy®

Use in Specific Populations

- **Pregnancy:** May cause fetal harm. When pregnancy is recognized, discontinue Wegovy®. Discontinue Wegovy® in patients at least 2 months before a planned pregnancy
- **Pediatric:** Adverse reactions with Wegovy® in pediatric patients aged 12 years and older were similar to those reported in adults. Pediatric patients ≥12 years of age treated with Wegovy® had greater incidences of cholelithiasis, cholecystitis, hypotension, rash, and urticaria compared to adults treated with Wegovy®

Please see additional Important Safety Information throughout. Please see accompanying Prescribing Information, including Boxed Warning.

novo nordisk®

ONCE-WEEKLY wegovy® semaglutide injection 2.4 mg